Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The invention relates to new quinoxaline, quinoline and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The invention relates to new quinoxaline, quinoline and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: A method is provided for determining whether an agent is capable of inducing a DNA lesion in a eukaryotic cell, including exposing the eukaryotic cell to the agent and determining whether an HR23 protein-binding molecule accumulates in the cell, where the HR23 protein-binding molecule is preferably xeroderma pigmentosum group C (XPC), 3-methyladenine DNA glycosylase (MAG), CREB, p53, or a functional part, derivative, and/or analogue thereof. Preferably the cell overexpresses HR23A and/or HR23B protein. A rapid and sensitive test is provided with significant advantages over the Ames test. A method is provided for determining whether an agent is capable of inhibiting a cellular process, the process resulting in accumulation of HR23 protein-binding molecule within a cell. A method for determining whether a cell has an impaired DNA repair system is provided. An impaired DNA repair system is indicative for diseases such as xeroderma pigmentosum, cockayne syndrome, and/or trichothiodystrophy.

Abstract: The current invention pertains to a method for screening and discovery of compounds capable of inhibiting, preventing, delaying or reducing genome maintenance disorders and consequences thereof, in particular ageing related symptoms and disorders. The current invention provides a method for screening and discovery of compounds that are capable of inhibiting, preventing, delaying or reducing genome maintenance disorders and consequences thereof. The invention exploits animal models that comprise deficiencies in their genome maintenance systems, such as DNA repair systems, and display premature, enhanced, accelerated or segmental ageing phenotypes. These animal models can be advantageously applied to screen compounds and thereby develop schemes of intervention to treat, delay, inhibit, prevent or cure ageing related symptoms. The current invention thus provides a new and powerful tool to screen aid/or discover therapeutically active compounds to treat ageing related symptoms and diseases.

Abstract: The present invention pertains to a nucleic acid sequence encoding a human TFIIH 8 kDa subunit and related sequences. The nucleic acids may be used in methods for producing a TFIIH subunit, as well as in methods for diagnosing or treating transcription and NER deficiencies, in particular in some forms of trichothiodystrophy (TTD). The hTFB5/TTDA gene and encoded protein may be used for therapy or genetherapy products, aimed at treating congenital NER disorders and may also be used in methods of diagnosis of disorders in basal transcription, NER and TCR activity in mammals, using molecular probes or antibodies specific for TTDA.

Abstract: A method for determining whether an agent is capable of inducing a DNA lesion in a eukaryotic cell, including: —exposing at least one eukaryotic cell to said agent, and —determining whether a HR23 protein binding molecule accumulates within the cell. It is preferably determined whether xeroderma pigmentosum group C protein (XPC), 3-methyladenine DNA glycosylase (MAG), CREB, p53, or a functional part, derivative and/or analogue thereof, accumulates in the nucleus of the cell. Preferably, the cell is overexpressing a HR23A and/or HR23B protein. With a method of the invention, a rapid and sensitive test is provided with significant advantages over the widely used Ames test.